Clearwater Capital Advisors LLC boosted its holdings in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 24.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 394,599 shares of the company’s stock after purchasing an additional 77,448 shares during the quarter. Clearwater Capital […]
07.11.2023 - ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced new data showing that the company’s Memory Cytokine-Enriched Natural Killer cells (M-ceNK) may provide benefit to patients with small cell lung cancer and . Seite 1
Investors in Culver City-based immunotherapy company ImmunityBio Inc. have recently been buoyed by the company’s announcements that it resubmitted – and the Food and Drug Administration has accepted – its application for review of its lead drug candidate to treat a type of bladder cancer.
Triple-Negative Breast Cancer Clinical Trial Pipeline Insights | 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.